ABT-263 crystalline forms
US8513243B2 · kind B2 · utility
2Cited by
4References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2011 |
| Grant date | Aug 20, 2013 |
| Priority date | — |
| Expiry date | Aug 24, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.